Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Nieto, Karen ^a   Weghofer, Margit ^b   Sehr, Peter ^c   Ritter, Mirko ^b,e   Sedlmeier, Sebastian ^b   Karanam, Balasubramanyam ^d   Seitz, Hanna ^a   Müller, Martin ^a   Kellner, Markus ^b,f   Hörer, Markus ^b,g   Michaelis, Uwe ^b   Roden, Richard B S ^d   Gissmann, Lutz ^a   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MediGene AG   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ROCHE DIAGNOSTICS GMBH   (Germany)

^f GE HEALTHCARE   (Germany)

^g Rentschler Biotechnologie GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONTANIDE ISA 51; PROTEIN VP3; WART VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG DETERMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG SCREENING; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; FREEZE DRYING; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; IMMUNOGENICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; VIRION; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PAPILLOMAVIRIDAE; RABBITS; VIRAL VACCINES; VIRION;

ANIMALIA; HUMAN PAPILLOMAVIRUS; MIRIDAE; MUS; ORYCTOLAGUS CUNICULUS;

EID: 84862988249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039741     Document Type: Article

References (42)

1. Zur Hausen H, (2006) Infections causing human cancer. Weinheim-New York: Wiley-VCH 1-517 p.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
3. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, et al. (2009) Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 27: 1949-1956.
4. Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, et al. (2011) The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology 409: 348-359.
5. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, et al. (2007) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358: 266-272.
6. Campo MS, O'Neil BW, Grindlay GJ, Curtis F, Knowles G, et al. (1997) A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology 234: 261-266.
7. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T, (1999) Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73: 6188-6190.
8. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270: 254-257.
9. Schellenbacher C, Roden R, Kirnbauer R, (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83: 10085-10095.
10. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, et al. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 105: 5850-5855.
11. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101: 782-792.
12. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, et al. (2002) The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 99: 10405-10410.
13. Sonntag F, Schmidt K, Kleinschmidt JA, (2010) A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 107: 10220-10225.
14. Sonntag F, Kother K, Schmidt K, Weghofer M, Raupp C, et al. (2011) The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol 85: 12686-12697.
15. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, et al. (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712.
16. Girod A, Ried M, Wobus C, Lahm H, Leike K, et al. (1999) Genetic capsid modifications allow efficient re-targeting of adeno- associated virus type 2. Nat Med 5: 1052-1056.
17. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, et al. (2000) Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74: 8635-8647.
18. Muzyczka N, Warrington KH Jr, (2005) Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 16: 408-416.
19. Michelfelder S, Trepel M, (2009) Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 67: 29-60.
20. Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ, (2010) AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 10: 319-340.
21. Boucas J, Lux K, Huber A, Schievenbusch S, von Freyend MJ, et al. (2009) Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations. J Gene Med 11: 1103-1113.
22. Naumer M, Ying Y, Michelfelder S, Reuter A, Trepel M, et al. (2011) Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions. Hum Gene Ther.
23. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81: 13927-13931.
24. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM, (2009) Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199: 381-390.
25. Calcedo R, Morizono H, Wang L, McCarter R, He J, et al. (2011) Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 18: 1586-1588.
26. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83: 2067-2074.
27. Culp TD, Budgeon LR, Marinkovich MP, Meneguzzi G, Christensen ND, (2006) Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol 80: 8940-8950.
28. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT, (2008) Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 82: 4638-4646.
29. Day PM, Lowy DR, Schiller JT, (2008) Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol 82: 12565-12568.
30. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, et al. (2007) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81: 11585-11592.
31. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, et al. (2005) Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337: 365-372.
32. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270: 254-257.
33. Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, et al. (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25: 2001-2010.
34. McKee AS, Munks MW, Marrack P, (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27: 687-690.
35. Guy B, (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5: 505-517.
36. Kuck D, Lau T, Leuchs B, Kern A, Muller M, et al. (2006) Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 80: 2621-2630.
37. Aucoin MG, Jacob D, Chahal PS, Meghrous J, Bernier A, et al. (2007) Virus-like particle and viral vector production using the baculovirus expression vector system/insect cell system: adeno-associated virus-based products. Methods Mol Biol 388: 281-296.
38. Bartel M, Schaffer D, Buning H, (2011) Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol 2: 204.
39. Pear WS, Nolan GP, Scott ML, Baltimore D, (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90: 8392-8396.
40. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.
41. Guyard-Dangremont V, Tenekjian V, Chauhan V, Walter S, Roy P, et al. (1999) Immunochemical evidence that cholesteryl ester transfer protein and bactericidal/permeability-increasing protein share a similar tertiary structure. Protein Sci 8: 2392-2398.
42. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861.